These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38935360)

  • 21. Schnitzler Syndrome: a Review.
    Gusdorf L; Lipsker D
    Curr Rheumatol Rep; 2017 Aug; 19(8):46. PubMed ID: 28718061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential role for interleukin-1 in the cardio-renal syndrome.
    Buckley LF; Canada JM; Carbone S; Trankle CR; Kadariya D; Billingsley H; Wohlford GF; Kirkman DL; Abbate A; Van Tassell BW
    Eur J Heart Fail; 2019 Mar; 21(3):385-386. PubMed ID: 30666820
    [No Abstract]   [Full Text] [Related]  

  • 23. The interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brain.
    Moynagh PN
    J Anat; 2005 Sep; 207(3):265-9. PubMed ID: 16185251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of interleukin-1 release and activity by the rat seminal vesicle protein SV-IV.
    Vuotto ML; Peluso G; Mancino D; Colonna G; Facchiano A; Ielpo MT; Ravagnan G; Metafora S
    J Leukoc Biol; 1993 Mar; 53(3):214-22. PubMed ID: 8384236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Injectable biomaterials for delivery of interleukin-1 receptor antagonist: Toward improving its therapeutic effect.
    Clements AEB; Murphy WL
    Acta Biomater; 2019 Jul; 93():123-134. PubMed ID: 31029831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pentamidine: an inhibitor of interleukin-1 that acts via a post-translational event.
    Rosenthal GJ; Corsini E; Craig WA; Comment CE; Luster MI
    Toxicol Appl Pharmacol; 1991 Mar; 107(3):555-61. PubMed ID: 2000641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.
    Ridker PM
    Circ Res; 2016 Jan; 118(1):145-56. PubMed ID: 26837745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of interleukin-1beta and interleukin-1beta inhibitor release by human airway epithelial cells.
    Yang Y; Bin W; Aksoy MO; Kelsen SG
    Eur Respir J; 2004 Sep; 24(3):360-6. PubMed ID: 15358691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface "receptor" with anti-interleukin-1 function.
    Re F; Sironi M; Muzio M; Matteucci C; Introna M; Orlando S; Penton-Rol G; Dower SK; Sims JE; Colotta F; Mantovani A
    J Exp Med; 1996 Apr; 183(4):1841-50. PubMed ID: 8666940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-1 and interleukin-1 antagonism in sepsis, systemic inflammatory response syndrome, and septic shock.
    Pruitt JH; Copeland EM; Moldawer LL
    Shock; 1995 Apr; 3(4):235-51. PubMed ID: 7600191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The search for inhibitors of interleukin-1 based on the sequence of interleukin-1 receptor antagonist.
    Wieczorek Z; Kluczyk A; Slon-Usakiewicz JJ; Siemion IZ
    Biomed Pept Proteins Nucleic Acids; 1996-1997; 2(4):123-9. PubMed ID: 9575352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-1 Blockade in Cardiovascular Diseases: From Bench to Bedside.
    Buckley LF; Abbate A
    BioDrugs; 2018 Apr; 32(2):111-118. PubMed ID: 29549570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monotonicity of interleukin-1 receptor-ligand binding with respect to antagonist in the presence of decoy receptor.
    Gnacadja G; Shoshitaishvili A; Gresser MJ; Varnum B; Balaban D; Durst M; Vezina C; Li Y
    J Theor Biol; 2007 Feb; 244(3):478-88. PubMed ID: 17011587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human interleukin-1 receptor antagonist. High yield expression in E. coli and examination of cysteine residues.
    Steinkasserer A; Solari R; Mott HR; Aplin RT; Robinson CC; Willis AC; Sim RB
    FEBS Lett; 1992 Sep; 310(1):63-5. PubMed ID: 1388125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p38 MAPK as a potential therapeutic target for inflammatory osteolysis.
    Wei S; Siegal GP
    Adv Anat Pathol; 2007 Jan; 14(1):42-5. PubMed ID: 17198310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is interleukin-1 a good target for therapeutic intervention in intervertebral disc degeneration: lessons from the osteoarthritic experience.
    Goupille P; Mulleman D; Chevalier X
    Arthritis Res Ther; 2007; 9(6):110. PubMed ID: 18086327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preterm Birth and Neonatal Injuries: Importance of Interleukin-1 and Potential of Interleukin-1 Receptor Antagonists.
    Nadeau-Vallee M; Obari D; Beaudry-Richard A; Sierra EM; Beaulac A; Maurice N; Olson DM; Chemtob S
    Curr Pharm Des; 2017; 23(40):6132-6141. PubMed ID: 28847304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-interleukin-1 therapy in rheumatic diseases.
    Dayer JM; Feige U; Edwards CK; Burger D
    Curr Opin Rheumatol; 2001 May; 13(3):170-6. PubMed ID: 11333344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.
    Pascual V; Allantaz F; Arce E; Punaro M; Banchereau J
    J Exp Med; 2005 May; 201(9):1479-86. PubMed ID: 15851489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drugs for gout.
    Med Lett Drugs Ther; 2014 Mar; 56(1438):22-4. PubMed ID: 24791281
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.